JP2005068010A5 - - Google Patents

Download PDF

Info

Publication number
JP2005068010A5
JP2005068010A5 JP2003063378A JP2003063378A JP2005068010A5 JP 2005068010 A5 JP2005068010 A5 JP 2005068010A5 JP 2003063378 A JP2003063378 A JP 2003063378A JP 2003063378 A JP2003063378 A JP 2003063378A JP 2005068010 A5 JP2005068010 A5 JP 2005068010A5
Authority
JP
Japan
Prior art keywords
risedronate
pharmaceutical composition
unit dose
composition according
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003063378A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005068010A (ja
Filing date
Publication date
Priority claimed from GBGB9717590.5A external-priority patent/GB9717590D0/en
Priority claimed from GBGB9717850.3A external-priority patent/GB9717850D0/en
Application filed filed Critical
Publication of JP2005068010A publication Critical patent/JP2005068010A/ja
Publication of JP2005068010A5 publication Critical patent/JP2005068010A5/ja
Pending legal-status Critical Current

Links

JP2003063378A 1997-07-22 2003-03-10 骨吸収を抑制する方法 Pending JP2005068010A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5335197P 1997-07-22 1997-07-22
US5353597P 1997-07-23 1997-07-23
GBGB9717590.5A GB9717590D0 (en) 1997-08-20 1997-08-20 Oral method for treating or preventing abnormal bone resorption
GBGB9717850.3A GB9717850D0 (en) 1997-08-22 1997-08-22 Oral method for treating or preventing abnormal bone resorption

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP50991499A Division JP3479780B2 (ja) 1997-07-22 1998-07-17 骨吸収を抑制する方法

Publications (2)

Publication Number Publication Date
JP2005068010A JP2005068010A (ja) 2005-03-17
JP2005068010A5 true JP2005068010A5 (https=) 2005-06-16

Family

ID=27451690

Family Applications (2)

Application Number Title Priority Date Filing Date
JP50991499A Expired - Lifetime JP3479780B2 (ja) 1997-07-22 1998-07-17 骨吸収を抑制する方法
JP2003063378A Pending JP2005068010A (ja) 1997-07-22 2003-03-10 骨吸収を抑制する方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP50991499A Expired - Lifetime JP3479780B2 (ja) 1997-07-22 1998-07-17 骨吸収を抑制する方法

Country Status (31)

Country Link
EP (5) EP1132088A3 (https=)
JP (2) JP3479780B2 (https=)
KR (3) KR20030097611A (https=)
CN (3) CN1602879A (https=)
AT (2) ATE209037T1 (https=)
AU (1) AU8493698A (https=)
BG (1) BG66282B1 (https=)
BR (1) BR9810779A (https=)
CA (1) CA2294595C (https=)
CY (2) CY1107535T1 (https=)
DE (6) DE01201911T1 (https=)
DK (2) DK0998292T3 (https=)
EA (1) EA004544B2 (https=)
EE (1) EE05603B1 (https=)
ES (3) ES2164447T3 (https=)
HK (4) HK1042230A1 (https=)
ID (1) ID24096A (https=)
IL (1) IL133535A0 (https=)
IS (3) IS5315A (https=)
LU (2) LU91222I2 (https=)
NL (2) NL300223I1 (https=)
NO (1) NO20000323L (https=)
NZ (1) NZ501807A (https=)
PL (1) PL195272B1 (https=)
PT (2) PT1175904E (https=)
SG (2) SG109478A1 (https=)
SI (1) SI0998292T1 (https=)
SK (1) SK932000A3 (https=)
TR (1) TR200000145T2 (https=)
UY (1) UY25950A1 (https=)
WO (1) WO1999004773A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW476649B (en) 1998-12-25 2002-02-21 Yamanouchi Pharma Co Ltd Pharmaceutical composition for treating bone disease of multiple myeloma
KR100763064B1 (ko) * 1999-05-21 2007-10-04 노파르티스 아게 제약 조성물 및 용도
ES2337545T3 (es) * 1999-07-19 2010-04-27 Toray Industries, Inc. Farmacos para enfermedades periodontales.
US6978894B2 (en) 1999-12-20 2005-12-27 Merck & Co., Inc. Blister package for pharmaceutical treatment card
AU2270101A (en) * 1999-12-20 2001-07-03 Merck & Co., Inc. Pharmaceutical kit
MXPA02009924A (es) * 2000-04-07 2004-08-19 Univ Texas Composiones unicas de fosfolipidos de ion anfoterico y bisfosfonatos y uso de las composiciones como sistemas de suministro de bisfosfato con toxicidad gi reducida.
CA2410201C (en) 2000-06-20 2010-10-26 Novartis Ag Zoledronic acid or salts thereof for use in the treatment of conditions of abnormally increased bone turnover
EP1591122B1 (en) * 2000-06-20 2012-09-26 Novartis AG Method of administering bisphosphonates
US6638920B2 (en) * 2000-07-21 2003-10-28 Merck & Co., Inc. Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
SE0101379D0 (sv) 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
PT1392325E (pt) * 2001-05-02 2006-10-31 Novartis Ag Metodo de administracao de bifosfonatos por inalacao no tratamento ou na prevencao da reabsorcao ossea e da osteoporose
RU2387451C2 (ru) * 2002-05-10 2010-04-27 Ф.Хоффманн-Ля Рош Аг Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
WO2005027921A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a bisphosphonate
WO2005072747A1 (ja) * 2004-02-02 2005-08-11 Ono Pharmaceutical Co., Ltd. 骨吸収抑制剤
CA2622322A1 (en) * 2005-09-16 2007-03-22 Selamine Ltd Bisphosphonate formulation
US9592195B2 (en) * 2010-12-06 2017-03-14 Effrx Pharmaceuticals Sa Stable effervescent bisphosphonate formulations with rapid solubilization characteristics
CN106924257B (zh) * 2017-03-14 2019-11-19 湖南赛隆药业有限公司 质子泵抑制剂和抗骨质疏松药的复合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL84731A0 (en) * 1986-12-19 1988-05-31 Norwich Eaton Pharma Heterocycle-substituted diphosphonic acids and salts and esters and pharmaceutical compositions containing them
SE8704436D0 (sv) * 1987-11-13 1987-11-13 Pm Konsult Handelsbolag Anvendning av antisekretoriska substanser for nya indikationer
DE59202126D1 (de) * 1991-07-01 1995-06-14 Gergely Gerhard Verfahren zur Herstellung einer pharmazeutischen Zubereitung mit wenigstens zwei verschiedenen Wirkstoffen und Verwendung einer solchen Zubereitung.
HU227530B1 (en) * 1991-11-22 2011-07-28 Warner Chilcott Company Delayed-release compositions containing risedronate and process for their production
US5270365A (en) * 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate
US5294433A (en) * 1992-04-15 1994-03-15 The Procter & Gamble Company Use of H-2 antagonists for treatment of gingivitis
EP0648120B1 (en) * 1992-06-30 1997-12-29 PROCTER & GAMBLE PHARMACEUTICALS, INC. Use of phosphonates for the treatment of osteoporosis
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
JPH11506750A (ja) * 1995-06-06 1999-06-15 メルク エンド カンパニー インコーポレーテッド 慢性関節リウマチに係わる骨欠損に対するビスホスホネート療法
EP0939624B1 (en) * 1996-05-17 2003-12-17 Merck & Co., Inc. Effervescent bisphosphonate formulation

Similar Documents

Publication Publication Date Title
JP2005068010A5 (https=)
JP2006504795A5 (https=)
ES2247123T3 (es) Metodo para administrar bisfosfonatos.
HRP20130057T1 (hr) Lijeäśenje progresivne neurodegenerativne bolesti ibudilastom
JP2013121983A5 (https=)
CA2434484A1 (en) Compositions comprising ibuprofen and diphenhydramine to treat pain-associated sleep disturbances
ATE350040T1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin
JP2002509888A5 (https=)
IL205262A (en) Use of Risderdone Acid or its Pharmaceutical Salt to produce oral medication once a month for the prevention and treatment of osteoporosis
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
JP2013231087A5 (https=)
DE69940557D1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
BRPI0516718A (pt) forma de dosagem de ibuprofeno de liberação modificada
FR2878161B1 (fr) Forme medicamenteuse orale, solide et concue pour eviter le mesusage
ES2168241T1 (es) Preparacion farmaceutica que contiene tolperisona para administrar por via oral.
WO2006029036A3 (en) Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
AP2003002763A0 (en) Controlled release formulations for oral administration
ATE543491T1 (de) Kombinationspräparat enthaltend ibuprofen und paracetamol
RU2007103306A (ru) Композиции на основе ризедроната и способы их применения
JPH10147529A5 (https=)
JP2002540148A5 (https=)
RU2005105691A (ru) Пероральное введение кальцитонина
MXPA04004907A (es) Composiciones de acetaminofen.
RU2006131553A (ru) Комбинация(а) ингибитора топоизомеразы днк и (б) ингибитора iap
HRP20211661T1 (hr) Igmezin, namijenjen upotrebi u liječenju alzheimerove bolesti